CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2018—GlobalData says Celgene’s acquisition of Juno Therapeutics in January, for $9 billion, has put the company in a “good position to be a frontrunner in the chimeric antigen receptor-T cell space.” Celgene stands to benefit from Juno’s expertise and ongoing work in addressing concerns surrounding CAR-T, according to a release from GlobalData, a market research consulting company.
Celgene plans to boost its lymphoma portfolio with JCAR017, a CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. The company looks to add $3 billion in sales pending the drug’s regulatory approval in the U.S., which is expected in 2019.
Celgene, 908-673-9000